Thyreotoxikose bei langjähriger Multipler Sklerose? – Fallstricke der MS-Therapie mit Biotin

Zusammenfassung

Hochdosis-Biotin ist ein neuartiger Wirkansatz für Patienten mit progredienter Multipler Sklerose (MS), der aktuell in klinischen Studien getestet wird. Artifizielle Veränderungen von Labortests sind eine häufige Komplikation. Wir berichten von einem 44-jährigen Patienten mit vermeintlicher Thyreotoxikose unter Hochdosis-Biotintherapie. Durch potenzielle Interaktionen mit Labortests ist der Einsatz von hochdosiertem Biotin nur mit Vorsicht unter Berücksichtigung von Risikofaktoren (z. B. kardiale Erkrankungen) und erst nach intensiver Beratung sinnvoll. Das Mitführen einer Kurzinformation bei den Ausweispapieren ist anzuraten.

Abstract

High-dose biotin is a new therapeutic approach for patients with progressive multiple sclerosis, currently being evaluated in clinical trials. Interference with laboratory tests is a common complication. We report on a 44-year-old male patient with putative thyrotoxicosis during therapy with high-dose biotin. Due to possible interactions with laboratory tests, high-dose biotin can only be recommended after individual risk-benefit assessment (e. g. cardiovascular disease) and intensive counseling. It is advisable for patients to carry a short medical document about high-dose biotin and its laboratory interactions.

Schlüsselwörter

Multiple Sklerose - Biotin - Laborwert

Keywords

multiple sclerosis - biotin - laboratory value

• Literatur

• 1 Sedel F, Papeix C, Bellanger A. et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015; 4: 159-169
• 2 Sedel F, Bernard D, Mock DM. et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology 2016; 110: 644-653
• 3 Tourbah A, Lebrun-Frenay C, Edan G. et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler 2016; 22: 1719-1731
• 4 Minkovsky A, Lee MN, Dowlatshahi M. et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep 2016; 2: e370-e373
• 5 Siddiqui U, Egnor E, Sloane JA. Biotin supplementation in MS clinically valuable but can alter multiple blood test results. Mult Scler 2017; 23: 619-620
• 6 Trambas CM, Sikaris KA, Lu ZX. A caution regarding high-dose biotin therapy: misdiagnosis of hyperthyroidism in euthyroid patients. Med J Aust 2016; 205: 192
• 7 Elston MS, Sehgal S, Du Toit S. et al. Factitious gravesʼ disease due to biotin immunoassay interference – a case and review of the literature. J Clin Endocrinol Metab 2016; 101: 3251-3255
• 8 Barbesino G. Misdiagnosis of gravesʼ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid 2016; 26: 860-863
• 9 Kummer S, Hermsen D, Distelmaier F. Biotin treatment mimicking graves' disease. N Engl J Med 2016; 375: 704-706
• 10 Willeman T, Casez O, Faure P. Biotin in multiple sclerosis and false biological hyperthyroidism: Mind the interference. Rev Neurol (Paris) 2017; 173: 173-174
• 11 Cusini C, Sassi L, De Paola G. et al. Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis. J Endocrinol Invest 2017; 40: 889-890
• 12 Medday Pharmaceuticals. Treatment with Qizenday may interfere with some laboratory tests. Im Internet: http://medday-lab.com [Stand 30.01.2018]
• 13 FDA. Biotin (Vitamin B7): Safety Communication – May interfere with Lab Tests. Posted 11/28/2017 – Safety Communication – FDA
• 14 Samarasinghe S, Meah F, Singh V. et al. Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks. Endocrine Practice 2017; 23: 989-998
• 15 Holmes EW, Samarasinghe S, Emanuele N. et al. Biotin interference in clinical immunoassays: a cause for concern. Arch Pathol Lab Med 2017; 141: 1459-1460